Table 1

Data from randomized placebo-controlled trials of DPP-4 inhibitors and the risk of HF

StudyYearDPP-4 inhibitorPopulationSample sizeMedian follow-up (years)Hospitalization for HF
Rate (no. per 100 PYs)HR (95% CI)
DPP-4 inhibitorPlacebo
SAVOR-TIMI 53 (5,6)2013, 2014SaxagliptinCVD or multiple CVD risk factors16,4922.11.71*1.36*1.27 (1.07–1.51)
EXAMINE (7,8)2013, 2015AlogliptinPost-ACS5,3801.52.692.281.19 (0.90–1.58)
 With history of HF1,5335.605.851.00 (0.71–1.42)
 With no history of HF3,8471.530.861.76 (1.07–2.90)
TECOS (9)2015SitagliptinCVD14,6713.01.071.091.00 (0.83–1.20)
  • ACS, acute coronary syndrome; PYs, person-years.

  • *Estimated using the total person-years of follow-up reported for each group (16,884 for saxagliptin and 16,761 for placebo).

  • †Estimated using the median duration of follow-up for the trial.

  • ‡Adjusted for baseline history of HF.